5th Cytokine-Based Drug Development Summit 2024

Memo

While leading cytokine therapeutic developers are using next-generation cytokine engineering technologies to tackle enduring efficacy and toxicity challenges to take their molecules through the clinic, the field is also looking to novel targets, novel cytokines and an expanded disease focus. As we enter a new era for cytokine therapies, armed with more cutting-edge technologies than ever before and enhanced translational understandings, the field is re-energizing the cytokine space to bring more life-changing drugs to patients. Curating learnings from previous experiences, the 5th Cytokine-Based Drug Development Summit returns as the only industry dedicated cytokine meeting with a disease agnostic approach. The packed 3-day agenda will be addressing topics ranging from oncology to autoimmune and infectious diseases. This dedicated meeting brings together most influential thought leaders from Xilio Therapeutics, Pfizer, Regeneron, Deka Biosciences, Moderna, and others to address your pressing challenges in delivery, efficacy, and toxicity. Join them to delve into the most exciting opportunities arising from mRNA cytokines, 'cis-demasking' technologies, novel computational protein design approaches, and beyond.   URLs:Tickets: https://go.evvnt.com/2140304-2?pid=5569Brochure: https://go.evvnt.com/2140304-3?pid=5569 Date and Time: On Tue, 21 May 2024 09:00 - Thu, 23 May 2024 16:25 Venue details: Wyndham Boston Beacon Hill, 5 Blossom Street, Boston, Massachusetts, 02114, United States Prices:Conference Only - Drug Developer: USD 2999.00,Conference + Pre - Conference Workshop Day - Drug Developer: USD 4197.00,Conference Only - Service Provider: USD 3699.00,Conference + Pre - Conference Workshop Day - Service Provider: USD 5097.00,Conference Only - Academic: USD 2599.00,Conference + Pre - Conference Workshop Day - Academic: USD 3597.00 Speakers: Aaron Meyer, Assistant Professor, UCLA, Audrey Le Floc’h, Associate Director, Regeneron, Bertolt Kreft, Chief Scientific Officer, Bright Peak Therapeutics, Carsten Krieg, Assistant Professor, Medical University South Carolina, Christian Plank, Chief Technology, Officer Ethris, Dane Wittrup, Associate Director of Engineering, MIT, Edward Hennessy, Senior Director Chemistry, Moderna, Fatima Hayat, Lead Research Analyst, Beacon, Fang Jin, Senior Scientist, Pfizer, George Coukos, Assistant Professor, Ludwig Cancer Centre , I-Ming Wang, Director-Translational Oncology, Pfizer, Jamie Spangler, Assistant Professor, Johns Hopkins University, John Mumm, Chief Executive Officer, Deka Biosciences, Jennifer O’Neil, Vice President-Translational Science, Xilio Therapeutics, Jijun Dong, Chief Scientific Officer, Salubris Bio, Jun Ishihara, Associate Professor, Imperial College London, Kate Jeffrey, Vice President-Immune Therapeutics Discovery, Moderna, Nicolas Poirier, Chief Executive Officer, OSE Therapeutics, Randolph Lopez, Co-founder and Chief Technology Officer, A-Alpha Bio, Tian Zhao, Vice President-Research and Development. Onconanomed, Uli Bialucha, Chief Scientific Officer. Xilio Therapeutics